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Abstract
Background: In vivo studies of HIV-1 pathogenesis and testing of antiviral strategies have been
hampered by the lack of an immunocompetent small animal model that is highly susceptible to HIV-
1 infection. Although transgenic rats that express the HIV-1 receptor complex hCD4 and hCCR5
are susceptible to infection, HIV-1 replicates very poorly in these animals. To demonstrate the
molecular basis for developing a better rat model for HIV-1 infection, we evaluated the effect of
human CyclinT1 (hCycT1) and CRM1 (hCRM1) on Gag p24 production in rat T cells and
macrophages using both established cell lines and primary cells prepared from hCycT1/hCRM1
transgenic rats.
Results: Expression of hCycT1 augmented Gag production 20–50 fold in rat T cells, but had little
effect in macrophages. Expression of hCRM1 enhanced Gag production 10–15 fold in macrophages,
but only marginally in T cells. Expression of both factors synergistically enhanced p24 production
to levels approximately 10–40% of those detected in human cells. R5 viruses produced in rat T cells
and macrophages were fully infectious.
Conclusion:  The expression of both hCycT1 and hCRM1 appears to be fundamental to
developing a rat model that supports robust propagation of HIV-1.
Background
A small-animal model of HIV-1 infection is needed for
development of prophylactic vaccines and more efficient
antiviral therapies. Current animal models of HIV infec-
tion, including non-human primates [1-4] and severe
combined immunodeficiency (SCID) mice transplanted
with fetal human cells [5,6], have made significant contri-
butions to our understanding of lentiviral pathogenesis
and to the development of vaccines and therapeutic
agents. However, these models have shortcomings, such
as their limited availability and high cost, their permissiv-
ity restricted to related retroviruses of nonhuman pri-
mates, as well as the absence or insufficient induction of
an immune response against HIV-1. Therefore, a better
small-animal model is needed.
Rodents may be useful models if they can be infected with
HIV-1. Because they are established experimental animals,
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inbred strains are available, and genetic manipulations
can be performed. However, a fully permissive model has
not been developed yet because of several inherent blocks
to HIV-1 replication in rodent cells. One major block to
HIV-1 replication is at the level of viral entry into the cell;
this may be overcome by introducing human CD4
(hCD4) and CCR5 (hCCR5) [7,8]. Indeed, transgenic (Tg)
rats expressing these receptors support some HIV-1 repli-
cation, albeit poorly [8], whereas Tg mice expressing
hCD4 and hCCR5 do not support any HIV replication [9].
These results suggest that rats may provide a good small-
animal model.
Studies on rodent cell-specific defects in the HIV-1 life
cycle after viral entry provide the molecular basis for
improving the propagation of HIV in rodents. However,
several studies using established cells lines [7,10,11] have
indicated that there are cell line specific defects in each
step of the viral life cycle. Moreover, technical difficulties
have hampered detailed analyses of the function of cellu-
lar cofactors in rodent T cells and macrophages, particu-
larly primary cells.
A study of the effects of rodent cellular factors on the func-
tion of the viral factors Tat and Rev will be of importance
because of the essential roles these proteins play in viral
propagation. Currently, controversial results have been
reported regarding the existence of a profound block affect-
ing Tat function in rodent cells. In early studies, human
CyclinT1 (hCycT1), identified as a Tat interacting protein
that is crucial for transcription during HIV-1 replication
[12], was expressed in mouse NIH 3T3 fibroblasts and tran-
scriptional activity was dramatically enhanced [13,14].
Moreover, hCycT1 Tg mice supported the enhanced expres-
sion of an integrated HIV-1 provirus [15]. A single amino
acid difference between human and mouse CyclinT1
(mCycT1), which has a tyrosine at residue 261 in place of
the cysteine amino acid in hCycT1, causes almost a com-
plete loss of Tat cofactor activity [13,14]. In contrast to
mouse cells, rat cells support significant amounts of Tat
function, even though rat CyclinT1 (rCycT1) has a tyrosine
at residue 261 and shares ~96% sequence homology with
mCycT1. Only 2–5 fold enhancement of Tat function by
overexpression of hCycT1 in rat cells has been reported.
Moreover, since the reported experiments lacked the
expression of rCycT1 as a control, uncertainty remains
whether it was the quantity or the quality of exogenously-
expressed hCycT1 which augmented Tat function
[7,16,17]. On the other hand, a substantial increase in Gag
protein levels upon hCycT1 expression in a rat myelo-
monocytic precursor cell line has been reported [18].
Rev function is involved in the expression of the unspliced
9-Kb and partially-spliced 4-Kb RNAs that encode the HIV
viral genome and the structural proteins [19]. Rev activity
that supports HIV-1 replication in rodent cells has also
been debated, although a reduction in the ratio of the
unspliced 9-kb transcript to the fully-spliced 2-kb viral
transcript in rodent cells has generally been reported
[7,10]. Moreover, the role of the rat counterpart of
hCRM1, which exports HIV RNAs in cooperation with Rev
[20,21], has been incompletely explored. Instead, overs-
plicing or a reduced stability of unspliced transcripts in
rodent cells compared to human cells has been proposed
[22], which has been reported to be repaired by the
expression of the human p32 protein [23].
In this study, we investigated the effect of human
CyclinT1 and CRM1 expressed in rat T cells and macro-
phages, including primary cells, in order to identify a
molecular basis for improving a rat model for HIV-1 infec-
tion. Our results show that co-expression of hCycT1 and
hCRM1 synergistically promotes Gag p24 production.
Interestingly, cell type specific requirements for these two
human factors were detected.
Methods
Cells and plasmids
Rat T cell lines, FPM1 [25] and C58(NT)D (ATCC TIB-236),
a rat macrophage line, NR8383 (ATCC CRL-2192), and
human T cell lines, Jurkat and Molt4R5, were used for prop-
agation of HIV-1. TZM-bl cells were used to measure the
infectivity of HIV-1 according to previously described pro-
cedures [26]. NR8383hCRM1, FPM1hCRM1, FPM1hCT,
and FPM1hCT/hCRM1 expressing hCRM1, hCycT1, or
both were constructed as described previously [40].
To construct hemagglutinin (HA)-tagged hCycT1,
pβCycT, which harbors the human cyclinT1 cDNA in the
pCXN2 vector, was used as a template for PCR with for-
ward (5'-ggtctagagcactatggagggagagaggaag-3') and reverse
(5'-gggaattcatgcatagtctggtacatcgtaggggtacttaggaaggggt-
ggaagtggtgg-3') primers with the following amplification
conditions: 2 min at 94°C, 30 cycles of 30 s at 94°C, 60 s
at 64°C, 2.5 min at 72°C, and a final extension for 10 min
at 72°C. The amplified DNA was digested and inserted
between the EcoRI and XbaI sites of pCXN2 [41].
Rat Cyclin T1 mRNA was extracted from rat ER-1 neo1
cells using the Absolute RNA extraction Kit (Stratagene)
and amplified by RT-PCR using the following primers: 5'-
ccgaattcaagcactatggagggagagaggaa-3' and 5'-ccgaattcatg
catagtctggtacatcgtaggggtacttaggaagaggtggaagaggtgg-3'. The
amplification conditions were: 94°C for 2 min, 30 cycles
of 15 s at 94°C, 30s at 60°C, 2.5 min at 68°C, and a final
extension for 5 min at 68°C. The amplified DNA was
digested and inserted into the EcoRI site of pCXN2.
To construct pSRαrCRM1-HA, pSRαrCRM1 was used for
PCR with the following primers: 5'-ctggaatcacttggcagct-Retrovirology 2009, 6:43 http://www.retrovirology.com/content/6/1/43
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gagctctacagagagagtcca-3' and 5'-
tatggtaccttaagcataatcaggaacatcgtatgggtagtcacacatttcttct-
gggatttc-3'. The amplification conditions were: 2 min at
94°C, 20 cycles of 30 s at 94°C, 1 min at 62°C, 2 min at
68°C, and a final extension for 10 min at 68°C. The
amplified DNA was digested and inserted into the SacI
and KpnI sites of pSRαrCRM1.
The following plasmids were used in this study: pSRα296
[42]; pCRRE [35]; pΔpol [24]; pMaxGFP (Amaxa) and
pCDMβ-gal [43]; pNL4-3 [30]; pYU-2 [28]; p89.6 [32];
pLAI-2 [31]; pYK-JRCSF [27]; and pNLAD8-EGFP [29].
pH1-luc (a gift from Dr. A. Adachi) contains a luciferase
coding sequence downstream of the HIV-1 LTR.
pSRαhCRM1-HA was a gift from Dr. T. Kimura.
Development of Human Cyclin T1 Transgenic (Tg) Rats
An hCycT1 BAC (RZPD;RZPDB737F032099D) was
microinjected into fertilized rat (F344) eggs. To identify
Tg rats, total genomic DNA extracted from rat tail snips
was examined by PCR using two sets of PCR primers with
one primer annealing the BAC backbone vector and the
other annealing the 5' or 3' end of hCyclin T1 genomic
DNA. Primers CTB3 (gccaacgctcaatccggttctcgc) and
CTGB3 (gctattttccagctgttctcgagtg) were used for the 5' end.
Primers CTB4 (ttattccctagtccaaggatgac) and CTGB4
(cagacaatagactatcaagacactgtg) were used for the 3' end.
PCR was performed using 500 ng of DNA as a template
with the following amplification conditions: 94°C for 2
min, 30 cycles of denaturation (94°C for 1 min), anneal-
ing (58°C for the 5' end primers and 54°C for the 3' end
primers, 30s), extension (72°C, 1 min), and a final exten-
sion (72°C, 5 min).
Preparation of rat primary cells and human cells
Rat primary T cells were enriched from splenocytes using
a nylon wool column. More than 95% of the cells were
CD3+ cells, as evaluated by Flow Cytometry (FACS Cali-
bur; Becton Dickinson). The cells were stimulated for 2
days with an anti-rat CD3 mAb (5 μg/ml) and an anti-rat
CD28 mAb (0.5 μg/ml) that had been coated on the cul-
ture plates. CD4+T cells were then isolated by negative
selection using anti-rat CD8 MicroBeads (Miltenyi Bio-
tec). Isolated CD4+CD8- T cells were >90% pure, as deter-
mined by staining with anti-rat-CD4 (BD Biosciences
Pharmingen) and anti-rat-CD8 (BD Biosciences Pharmin-
gen).
Rat peritoneal macrophages were isolated from rats that
had been treated with 3% thioglycollate for 3 days. The
macrophages were coated with anti-rat CD11b and iso-
lated using goat anti-mouse IgG MicroBeads (Miltenyi
Biotec). Isolated CD11b+ peritoneal cells were >90% pure,
as determined by staining with mouse anti-rat-ED2 (BD
Biosciences). Isolated CD11b+ ED2+ peritoneal cells were
cultured for 2 h at 37°C to allow them to adhere to the
plates.
Human peripheral blood mononuclear cells (PBMCs)
were isolated from healthy donors using Ficoll Paque Plus
(Amersham Biotechnology) density centrifugation. The
cells were activated with 5 μg/ml phytohemagglutinin-P
(PHA-P) (SIGMA) and 20 U/ml IL-2 (PeproTech EC) for 3
days at 37°C. Peripheral blood lymphocytes (hPBLs) were
harvested as non-adherent cells.
Human monocytes were isolated from PBMCs using anti-
CD14 conjugated to magnetic beads (Miltenyi Biotec),
and allowed to adhere on dishes at 37°C for 1 h in RPMI
1640 supplemented with 1% human serum. Human
monocyte-derived macrophages (MDMs) were then gen-
erated by incubation in RPMI 1640 supplemented with
15% FBS, antibiotics, and GM-CSF (10 U/ml) (R & D) for
5 days.
Electroporation
Cell lines (2 × 106) and primary T cells (1 × 107) were elec-
troporated in 100 μl of Nucleofector Solution (Cell line
Solution V, Mouse T cell and human T cell Nucleofector
kit, Amaxa Biosystems,) using the conditions (FPM1;T-03,
C58(NT)D;T-20, NR8383;T-27, and rat primary T;X-01,
Jurkat;X-01, Molt4R5;A-30, hPBL;U-14) and plasmids
described in the Figure Legends. After 48 h, p24 in the
supernatant and in cells was quantified using a p24 ELISA
kit (Zeptometrix). In some cases, the viruses were concen-
trated by centrifugation at 15,000 rpm for 90 min in a
microcentrifuge and p24 was quantitatively recovered
from the pellets.
Western Blotting
Cells were lysed in buffer containing 10 mM Tris-HCl, pH
7.4, 1 mM MgCl2, 0.5% NP40, and protease inhibitors or
sample buffer without mercaptoethanol and dye, and pro-
tein concentrations were determined by BCA assay. Sam-
ples containing 50 μg protein were then subjected to
Western blotting using anti-CycT1 (Novocastra Laborato-
ries Ltd), anti-CRM1 [42], anti-HA (Behringer), or anti-β-
actin (SIGMA).
Infection
Rat peritoneal macrophages and human MDMs were
seeded at a density of 5 × 105 cells/well in 24 well plates
and cultured for 1 day at 37°C. Macrophages were then
inoculated with VSV-G-coated NL43 and NLAD8-EGFP
(50 ng), which were prepared by transfection of pNL4-3
or pNLAD8-EGFP along with pVSV-G to 293 T cells with
Fugene6, in the absence or presence of 20 μM PMPA [44]
overnight at 37°C. Finally, cells were washed gently 5
times and 2 ml of RPMI containing 15% FCS with or with-
out PMPA was added.Retrovirology 2009, 6:43 http://www.retrovirology.com/content/6/1/43
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Effect of hCycT1 and hCRM1 expression in rat T cell lines (part 1) Figure 1
Effect of hCycT1 and hCRM1 expression in rat T cell lines (part 1). (A) FPM1 cells were electroporated with 2 μg 
pΔpol, 1 μg pMax-GFP, and 1 μg pCXN2, pCXN2hCycT1-HA, pβhCycT1, or pCXN2rCycT1-HA. After 2 days, p24 levels in 
the medium were measured by ELISA. The percentage of living cells was approximately 18% and approximately 95% of the liv-
ing cells were GFP+ based on FACS analysis. The ratio of p24 in the CycT1 containing samples relative to mock treated samples 
was calculated. The total amount of p24 in the hCycT-HA containing sample was 119 pg. Values are means of duplicate sam-
ples. rCycT1 and hCycT1 were detected by Western blotting using anti-HA. (B) FPM1 cells were electroporated with 2 μg 
pΔpol, 1 μg pMax-GFP, and 0.5 μg pSRα296, pSRα hCRM1-HA, pSRαrCRM1-HA, or pSRαhCRM1. The percentage of living 
cells was approximately 4%, and 60% of the living cells were GFP+. The total amount of p24 in the sample containing hCRM1 
was 146 pg. In the right panel, 1 μg pCNXhCycT1 was included. Values are means of duplicate samples. The total amount of 
p24 in the sample containing hCRM1 was 15.7 ng. (C) pSRα296, pSRαhCRM1-HA, or pSRαrCRM1-HA (0.5 μg) were electro-
porated into FPM1 and Molt4 cells, and 50 μg/ml cycloheximide was added after 24 h. The cells were then collected at 0, 6, and 
12 h after the drug addition, and analyzed by Western blotting. Various amounts of the cell lysates were used for blotting (25 
μg of hCRM1-HA containing FPM1, 5 μg rCRM1-HA containing FPM1, and 25 μg of hCRM1-HA or 10 μg of rCRM1-HA con-
taining Molt4, respectively).Retrovirology 2009, 6:43 http://www.retrovirology.com/content/6/1/43
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Results
Synergistic Effects of hCycT1 and hCRM1 in Rat T cell 
lines
Since controversial results regarding the activity of Tat in
rat cells have been reported, we compared the effect of
hCycT1 versus rCycT1expression in rat T cells. To express
the HIV-1 genome and CycT1 in rat T cells, we used the
electroporation of CycT1 and an HIV-1 genome express-
ing plasmid, since we experienced very low rates of HIV-1
infection even with VSV-G coated particles. In our hands,
electroporation was the only way to introduce enough
HIV genome into rat T cells. We co-electroporated pMax-
GFP or pCDM-βgal to monitor the efficiency of electropo-
ration. When we electroporated pΔpol, which was con-
structed by deleting 328 base pairs in the pol gene of the
infectious pNL43 genome [24], and HA-tagged hCycT1 or
rCycT1 into FPM1 cells, a rat CD4+ T cell line transformed
with HTLV-1 [25], Gag p24 production was enhanced sev-
eral fold in the presence of hCycT1-HA. However, hCycT1
expression was very low. In contrast, rCycT1-HA was effi-
ciently expressed, but did not alter Gag p24 production.
Since hCycT1-HA may be unstable, we next used an
untagged hCycT1 for co-electroporation. We detected a 40
fold enhancement of Gag production in the presence of
hCycT1 (Fig. 1A). The band corresponding to hCycT1 was,
however, hardly detected by Western blot analysis (data
not shown). The reason why untagged hCycT1 enhanced
expression more efficiently than hCycT1-HA is currently
unclear, because the intracellular amounts of these
hCycT1s cannot be exactly compared due to the different
abilities of the anti-HA mAb and anti-hCycT1 antibody.
Next, to assess Rev activity in rat T cells, we compared the
effects of hCRM1 and rCRM1 on HIV-1 propagation.
When we electroporated HA-tagged CRM1 expression
plasmids and pΔpol into FPM1 cells, p24 production was
not significantly increased. The level of hCRM1-HA
detected by Western blotting was very low. However, we
reproducibly observed a 2–4 fold enhancement of p24
production in cells transiently expressing untagged
hCRM1, but not rCRM1 (Fig. 1B). These results suggest
that endogenous rCRM1 supports p24 production less
efficiently than the hCRM1 and that Rev function is not
absolutely blocked in rat T cells. To examine the stability
of CRM1-HA, we added cycloheximide to inhibit transla-
tion in CRM1-transfected T cells and examined CRM1
protein levels over time. In both rat and human T cells,
hCRM1-HA was much less stable than rCRM1-HA (Fig.
1C), partly accounting for the lower amounts of hCRM1
(See Fig. 1B).
To examine the effects of both hCycT1 and hCRM1 on
HIV-1 propagation in rat T cells, including FPM1 and
C58(NT)D cells, we co-electroporated these expression
plasmids with pΔpol. Additionally, we co-transfected
pH1-Luc, which expresses the luciferase gene driven by
the HIV-1 LTR, to examine the effect of hCycT1 and
hCRM1 on Tat-directed gene expression. Expression of
hCycT1, but not hCRM1, enhanced LTR-derived expres-
sion several fold, consistent with the previously reported
functions of these proteins. Notably, the enhancement of
p24 production by hCycT1 was substantially greater than
that of the luciferase activity. Furthermore, levels of extra-
cellular p24 were more enriched than intracellular levels,
and hCycT1 synergistically cooperated with hCRM1 to
augment the synthesis of p24 by approximately 100 fold
(Fig. 2A and 2B). These results suggest that hCycT1
enhanced the transcription of the LTR-driven HIV-1 pre-
mRNA. Since the pre-mRNA is the source of mRNAs
encoding Gag, Tat and Rev, its increase may trigger posi-
tive feedback in the synthesis of HIV-1 pre-mRNA as a
result of increased Tat protein levels and in the amounts
of unspliced mRNA as a result of increased Rev protein
levels. Thus, Gag would be produced much more effi-
ciently than luciferase. Subsequently, the enhanced Gag
expression facilitates the more efficient release of viral par-
ticles. The level of p24 produced by rat T cells expressing
both hCycT1 and hCRM1 was approximately 25–33% of
the levels produced by the human T cell line Molt4 (data
not shown).
To examine the effect of hCycT1 and hCRM1 on HIV-1
propagation using a full length HIV-1 clone, we electropo-
rated pNL4-3 into FPM1 T cells that continuously
expressed hCycT1 and hCRM1, and then quantified the
production of p24. Again, hCycT1 greatly augmented p24
production, and hCRM1 had a moderate effect. Notably,
the levels of hCycT1 and hCRM1 expression in FPM1 cells
were similar to those in Molt4 cells (Fig. 2C). Thus,
expression of these human factors should support robust
HIV-1 propagation in rat T cells.
Synergistic Effects of hCycT1 and hCRM1 in rat 
macrophages
We examined the effect of hCycT1 and hCRM1 on p24
production and LTR-driven expression in the rat macro-
phage cell line NR8383, using the experimental
approaches described above. Transient expression of
rCRM1-HA in NR8383 cells did not affect p24 produc-
tion, whereas hCRM1-HA enhanced p24 production 5–10
fold, although the level of hCRM1-HA expression was
much less than that of rCRM1-HA (Fig. 3A). Expression of
hCycT1 enhanced p24 production by only a few fold. The
expression of hCycT1 was readily detected by Western
blotting (Fig. 3B), in contrast to the low levels in rat T
cells. Neither hCycT1 nor hCRM1 expression significantly
affected luciferase expression driven by the HIV LTR (Fig.
3C). We also detected a greater than 10 fold enhancement
of extracellular and intracellular p24 production in the
presence of untagged hCRM1 (Fig. 3C), but not rCRM1
(data not shown). When hCycT1 and hCRM1 were co-
expressed, they synergistically augmented p24 productionRetrovirology 2009, 6:43 http://www.retrovirology.com/content/6/1/43
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Effect of hCycT1 and hCRM1 expression in rat T cell lines (part 2) Figure 2
Effect of hCycT1 and hCRM1 expression in rat T cell lines (part 2). (A) FPM1 and (B) C58(NT)D cells were electro-
porated, as above, with the exception that 0.4 μg pH1-Luc and 0.2 μg pCDMβ-gal were used instead of pMax-GFP. LTR activity 
and transfection efficiency were measured by luciferase and β-gal assays using cell lysates. The luciferase/β-gal activity or the 
amount of p24 was calculated, and the value of the mock sample was normalized to 1. Values are means of triplicate samples 
and the SD was calculated. The amount of p24 in the FPM1 and C58(NT)D samples containing hCycT1/hCRM1 was 3.7 and 2.8 
ng, respectively. (C) FPM1 cells continuously expressing hCycT1 and hCRM1 were electroporated with 4 μg pNL4-3 and 1 μg 
pMaxGFP. The percentage of living cells was approximately 10%, and 50% of the living cells were GFP+. The amount of p24 in 
the FPM1hCT/hCRM1 sample was 6.0 ng. Approximately 10 μg of each cell lysate were subjected to Western blotting.Retrovirology 2009, 6:43 http://www.retrovirology.com/content/6/1/43
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by greater than 20–50 fold in NR8383 cells (Fig. 3B and
3C). The amount of extracellular p24 increased more than
intracellular p24, as seen in T cells, suggesting that the
increase in Gag expression facilitated more efficient
release of viral particles. These results clearly indicate that
hCRM1 augments p24 production in rat macrophages
more efficiently than hCycT1, in contrast to the effects of
the two proteins in rat T cell lines.
Infectivity of HIV-1 produced by rat cells
To investigate whether HIV-1 produced by rat cells is infec-
tious, we electroporated infectious HIV-1 molecular clones
into rat and human cells and evaluated the infectivity of the
progeny viruses using the indicator TZM-bl cells, which
express luciferase upon HIV infection [26]. Luciferase activity
versus inoculated p24 was used as a surrogate marker of
infectivity. Interestingly, R5 viruses produced in rat T cells,
including the JR-CSF [27], YU-2 [28], and NL-AD8 [29]
strains, were equally infectious compared to those produced
by human T cells, whereas rat T cell-derived ×4 and dual
tropic viruses such as NL4-3 [30], LAI-2 [31], and 89.6 [32]
varied in their infectivity. In contrast, both R5 and ×4 viruses
produced in the macrophage cell line exhibited infectivities
comparable to those from human cells (Fig. 4).
Characterization of hCycT1 and hCRM1 Tg rats
To examine the role of hCycT1 in primary cells, we con-
structed transgenic (Tg) rats that express hCycT1. Since the
regulation of cyclinT1 gene expression is complex [33], a
BAC harboring the entire human cyclinT1 gene, which is
assumed to contain all the regulatory sequences, was
microinjected into fertilized rat eggs. To confirm the
expression of hCycT1 in the Tg rats, cells isolated from
both thymus and spleen were analyzed by Western blot-
ting using anti-hCycT1. Thymocytes, but not splenocytes,
of Tg rats expressed hCycT1 (Fig. 5A). Since hCycT1 is
expressed during the activation of human lymphocytes
[33], we stimulated the splenocytes with anti-CD3 and
anti-CD28. Expression of hCycT1 was detected within 1
Synergistic effect of hCycT1 and hCRM1 in rat macrophage  cell lines Figure 3
Synergistic effect of hCycT1 and hCRM1 in rat macro-
phage cell lines. (A) NR8383 cells were electroporated as 
described in Fig. 1B. The percentage of living cells was approx-
imately 20–40%, and approximately 75% of the living cells 
were GFP+. The amount of p24 in the sample containing 
hCRM1-HA was 196 pg. Approximately 50 μg samples of the 
cell lysates were subjected to Western blotting as described in 
the Methods. (B) NR8383 cell lines were electroporated as 
described in Fig. 1A. The percentage of living cells was approx-
imately 15%, and approximately 60% of the living cells were 
GFP+. The amount of p24 in the sample containing hCRM1-
HA/hCycT1 was 56 pg. (C) NR8383 cell lines were electropo-
rated with 2 μg pΔpol, 0.4 μg pH1-Luc and 0.2 μg pCDMβ-gal 
along with or without 1 μg pβhCycT1 and 0.5 μg pSRαhCRM. 
pSRα296 was added to adjust the total amount of the plas-
mids. The amounts of p24 in the cell lysate and medium of the 
sample containing hCRM1/hCycT1 were 488 and 96 pg, 
respectively. Values are means of triplicate samples.
Infectivity of HIV-1 produced in rat and human cells Figure 4
Infectivity of HIV-1 produced in rat and human cells. 
The medium [containing 50 or 500 pg of p24] from the vari-
ous cell types electroporated with infectious clones was used 
to infect TZM-bl cells, and luciferase activity in the TZM-bl 
cells infected with various progeny viruses was normalized to 
that in cells infected with HIV-1 released from Jurkat cells. 
The relative infectivity of HIV-1 from Jurkat cells was normal-
ized to 1. N.D: not determined.Retrovirology 2009, 6:43 http://www.retrovirology.com/content/6/1/43
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day and peaked 2 days after stimulation (Fig. 5B). Interest-
ingly, rat splenocytes stimulated with phytohemaglutinin
(PHA) and IL-2 did not express hCyCT1 (data not
shown).
Expression of hCRM1 in Tg rats was also examined, using
a previously established Tg rat [34]. hCRM1 was expressed
in both thymocytes and splenocytes activated with anti-
CD3/CD28 (Fig. 5C). hCRM1 was not expressed in
unstimulated splenocytes (data not shown), consistent
with hCRM1 expression in human PBMC [34]. We further
characterized total T cells and CD4+CD8- T cells prepared
from double Tg rats in comparison to rat total T cells and
human CD4+CD8- T cells 2 days after stimulation. Both
hCycT1 and hCRM1 were expressed in activated
CD4+CD8- T cells prepared from the Tg rat, similar to
human CD4+CD8- T cells (Fig. 5C and 5D). Both hCycT1
and hCRM1 were expressed in rat peritoneal macrophages
at levels equivalent to expression in human monocyte-
derived macrophages (MDMs) (Fig. 5E).
Ex vivo p24 production in T cells derived from hCycT1/
CRM1 Tg rats
To investigate the effects of hCycT1 and hCRM1 on p24
production in primary T cells, we prepared T cells from
splenocytes of wild-type (WT) and Tg rats and stimulated
them with anti-CD3/CD28. As a control, isolated human
PBLs were activated. In these experiments we used pCRRE
[35], which harbors an HIV-1 genome with a deletion in
the region from pol to vpr, instead of pΔpol [24], since
introducing either pΔpol or the full-sized HIV-1 genome
into the primary T cells by any method, including electro-
poration or VSV-G coated virus, had limited success.
T cells derived from hCycT1 Tg rats produced approxi-
mately 10–15 fold more p24 than WT T cells. In T cells
derived from hCRM1 Tg rats, p24 production increased
approximately 3 fold over WT cells. T cells-derived from
hCycT1/CRM1 doubly Tg rats produced p24 at levels 24–
40 fold greater than WT, and this level was ~40% of that
produced by hPBLs (Fig. 6A). We further examined p24
production by CD4+CD8- T cells prepared from double Tg
rats in comparison to WT rat and human cells. CD4+CD8-
T cells prepared from double Tg rats produced p24 in the
medium approximately 180 fold more efficiently than WT
rat cells; this level was ~11% of the amount of p24 pro-
duced by human CD4+CD8- T cells (Fig. 6C). These results
indicate that the synergistic effects of hCycT1 and hCRM1
promoted the production of p24 in rat primary T cells ex
vivo.
When intracellular p24 was evaluated by ELISA, increases
of approximately 7 and 17 fold were observed in total T
and CD4+CD8- T cells, respectively (Fig. 6B and 6D), con-
siderably less than the amount of extracellular p24
described above. The ratio of extracellular p24 to intracel-
lular p24 increased gradually as p24 production
increased, suggesting a more efficient virus release from
the double Tg rat T cells compared to WT rat T cells.
Ex vivo p24 production in peritoneal macrophages derived 
from hCycT1/CRM1 Tg rats
To investigate HIV-1 propagation in macrophages derived
from Tg rats, we prepared CD11b+ED2+ peritoneal macro-
Characterization of hCycT1 and hCRM1 Tg rats Figure 5
Characterization of hCycT1 and hCRM1 Tg rats. (A) 
The expression of hCycT1 in spleen- and thymus-derived cells 
from WT or hCycT1 Tg rats was confirmed by Western blot-
ting using anti-hCycT1. (B) T cells derived from the spleen of 
WT or hCycT1 Tg rats were stimulated with anti-rat-CD3 and 
anti-rat-CD28. Cells were collected at the indicated times and 
subjected to Western blotting using anti-hCycT1. (C) The 
expression of hCycT1 and hCRM1 in spleen- and thymus-
derived cells (C), total T and CD4+CD8- T cells (D), and mac-
rophages (E) in WT or Tg rats was confirmed by Western 
blotting using anti-hCycT1 and anti-hCRM1. T cells derived 
from the spleen of WT or hCycT1 Tg rats were stimulated 
with anti-rat-CD3 and anti-rat-CD28.Retrovirology 2009, 6:43 http://www.retrovirology.com/content/6/1/43
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Quantification of p24 production in the total T cell fraction and CD4+CD8- T cell fraction derived from hCycT1/CRM1 Tg rats Figure 6
Quantification of p24 production in the total T cell fraction and CD4+CD8- T cell fraction derived from 
hCycT1/CRM1 Tg rats. Stimulated spleen-derived T cells from WT or Tg rats and hPBL were electroporated with 4 μg 
PCRRE and 1 μg pMax-GFP, and p24 production in the supernatants (A) and cell lysates (B) was measured by ELISA (left 
panel). The percentage of living cells was 30–40%, and 28–40% of the living cells were GFP+. The right panels represent the fold 
activation of Tg versus WT rats. Stimulated CD4+CD8- T cells derived from WT, hCycT1/CRM1 Tg rats, and human blood 
were electroporated, as above, and p24 production in the supernatants (C) and cell lysates (D) was measured. The percentage 
of living cells was ~10%, and 30–40% of the living cells were GFP+. Values are the means of duplicate samples.Retrovirology 2009, 6:43 http://www.retrovirology.com/content/6/1/43
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phages and subsequently infected the cells using HIV-1
pseudotyped with VSV G protein. Although WT peritoneal
macrophages produced a considerable amount of HIV-1
progeny virus in the absence of hCRM1 and hCycT1
expression, macrophages derived from hCycT1/CRM1
doubly Tg rats produced 6 fold higher levels of p24 at their
peak (Fig. 7A). This level corresponds to 20% of the
amount of p24 produced by human MDMs (data not
shown). Macrophages from hCRM1 Tg rats supported a
several fold increase in p24 production, but hCycT1
expression had a smaller effect. Macrophages treated with
PMPA, a reverse transcriptase inhibitor, did not produce
significant amounts of p24, confirming that the p24
measured represents production of progeny viruses and
not inoculum. The amount of intracellular p24 also
increased to some extent in the Tg rats, but to a lesser
extent than p24 levels in the medium (Fig. 7B). Approxi-
mately 67% of the p24 synthesized in the doubly Tg cells
was released into the medium and the ratio of extracellu-
lar p24 to intracellular p24 increased as viral production
increased (Fig. 7C).
The infectivity of the viruses, which were harvested 5 days
post infection, was evaluated using TZM-bl cells. Figure
7D shows that both R5 and ×4 viruses produced from rat
macrophages retained infectivity levels similar to those
from human PBLs and MDMs.
Discussion
In the present study, we demonstrated the effects of
hCycT1 and hCRM1 on augmentation of HIV-1 Gag pro-
duction in both established and primary rat T cells and
macrophages. hCycT1 enhanced p24 production pro-
foundly in rat T cells, suggesting that hCycT1 is an essen-
tial gene that should be included in the construction of a
rat model of HIV-1 infection. Although our results are in
contrast to the previous reports of only a 2–5 fold increase
in early gene expression in rat primary T cells and epithe-
lial cells expressing hCycT1 [7,10,16,17], the overall
effects stemmed from the increased HIV-1 pre-mRNA in
response to hCycT1 expression included an increase in
Tat/Rev proteins and enhanced efficiency of p24 release
from T cells. This may explain the remarkable enhance-
ment of p24 levels in the extracellular milieu. Our results
support and extend the effect of hCycT1 expressed in rat
primary T cells originally described by Michel et al [17]. In
contrast, hCycT1 expression in macrophages had only a
minor effect on p24 production. Since the level of LTR-
driven luciferase activity in NR8383 cells in the absence of
hCycT1 was similar to Molt4 cells (data not shown), the
high basal activity of LTR-driven gene expression may
explain the diminished effect of hCycT1 expression. These
data are consistent with the relatively high HIV-1 LTR
activity in primary macrophages [7,16,17]. Since rCycT1,
like mCycT1, has a tyrosine at residue 261 in place of the
hCycT1 cysteine [7], which is crucial for binding to the
TAR element, rCycT1 itself may not be functional in LTR-
driven expression. Instead, rat epithelial cells and macro-
phages may support transcription in a Tat independent
manner. Alternatively, other factors in these cells may
cooperate with rCycT1 for efficient LTR-driven expression.
The expression of hCRM1 in the rat macrophage line
NR8383 profoundly augmented the production of p24,
suggesting that Rev function is impaired and that inclu-
sion of the hCRM1 gene in construction of a rat model for
HIV-1 infection should be considered. Moreover, the pro-
found effects of hCRM1 expression have been observed in
several rat epithelial cell lines (data not shown); rCRM1
Quantification of p24 production in rat peritoneal macro- phages Figure 7
Quantification of p24 production in rat peritoneal 
macrophages. (A) Rat peritoneal macrophages or human 
MDMs were infected with VSV-G pseudotyped NL4-3 virus. 
The amount of p24 in the medium was then measured by 
ELISA. (B) The infected cells were harvested 12 days after 
infection and intracellular p24 levels were evaluated. (C) The 
ratio of the amount of extracellular to intracellular p24 was 
calculated. (D) Infectivity of viruses present in the medium 5 
days after infection was measured using TZM-bl cells. 
NLAD8-EGFP was used to infect 5 × 105 macrophages from 
double Tg rats or human PBL, and the medium was recov-
ered 5 days after infection. Values are the means of triplicate 
samples.Retrovirology 2009, 6:43 http://www.retrovirology.com/content/6/1/43
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may support Rev function less efficiently. However, the
effect of hCRM1 was not as great in T cell lines, primary T
cells, or macrophages, compared to the macrophage cell
line. These observations suggest that CRM1 function may
be affected by factors involved in the formation of gag
mRNA, such as the cell type-specific efficiency of splicing.
In mouse cells, defects in HIV particle formation and
release have been reported [11] due to incorrect transport
of gag mRNA from the nucleus to the cytoplasm [36]. The
release of viral particles from both primary rat T cells and
macrophages was inefficient when p24 production was
low. However, when p24 production was enhanced by
expression of hCycT1 in T cells or hCRM1/hCycT1 in mac-
rophages, p24 was released more efficiently. These results
suggest that the intracellular concentration of Gag protein
is critical for efficient virus formation. However, rat teth-
erin, which is resistant to Vpu-induced degradation, may
reduce the release of viral particles, although this effect
was demonstrated using tetherin overexpression [37].
Since we observed that the efficiency of viral release was
variable under different conditions (compare panels of
Fig. 6), the inhibitory effect of rat tetherin may be an
important subject for future study.
Both R5 and ×4 viruses produced from rat macrophages
are as infectious as those produced by human macro-
phages, consistent with the report of Keppler et al. [8]. In
contrast, ×4 and dual-tropic viruses that were produced in
rat T cells had varying infectivities, although several R5
strains produced in rat T cells were as infectious as human
T cell-produced viruses. These differences in infectivity
may be ascribed to the envelope because the AD8 strain
was constructed by substituting M-tropic env for the coun-
terpart  env  fragment in pNL4-3 [29]. Investigating the
causes of these differences in infectivity will enable us to
make a rat model that allows for propagation of various
strains of HIV-1.
The efficiency of the early steps of infection, including
reverse transcription, nuclear import, and integration in
macrophages and T cells of Sprague-Dawley rats is compa-
rable to human cells, in contrast to the low rate of integra-
tion in mouse T cells [8,16,38]. We have also efficiently
infected rat macrophages using VSV-G-coated viruses.
However, the very low rate of infection of primary T cells
from the rat F344 strain used in this study has hampered
our detailed analysis, and suggested that inhibitory factors
affecting viral penetration, similar to monkey Trim5α
[39], may be present. Further studies on the mode of HIV
infection in each rat strain will be required.
Conclusion
Expression of both hCycT1 and hCRM1 synergistically
enhanced p24 production in rat T cells and macrophages
to levels approximately 10–40% of those detected in
human cells. R5 viruses produced in the rat cells were
infectious. Moreover, the efficiency of the early steps of
HIV-1 infection in some rat cells has been reported to be
comparable to human cells [8,16]. Collectively, these
results suggest that rats that express human CD4, CCR5,
CycT1, and CRM1 may provide the basis for a good model
system that supports multiple cycles of HIV-1 infection.
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